Modulation of immune responses using adjuvants to facilitate therapeutic vaccination
Authors:
- Virgil SchijnsVSVirgil Schijns
- Alberto Fernández‐TejadaAFAlberto Fernández‐Tejada
- Ilias BouzalasIBIlias Bouzalas
- Sergey ChernyshSCSergey Chernysh
- Sveinbjorn GizurarsonSGSveinbjorn Gizurarson
- Ihsan GurselIGIhsan Gursel
- Žiga JakopinŽiga Jakopin
- Maria LawrenzMLMaria Lawrenz
- Cristina NativiCristina Nativi
- Stephane PaulSPStephane Paul
Open Access
- 28 June 2020
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 296 (1) , 169-190
Abstract
Therapeutic vaccination offers great promise as an intervention for a diversity of infectious and non‐infectious conditions. Given that most chronic health conditions are thought to have an immune component, vaccination can at least in principle be proposed as a therapeutic strategy. Understanding the nature of protective immunity is of vital importance, and the progress made in recent years in defining the nature of pathological and protective immunity for a range of diseases has provided an impetus to devise strategies to promote such responses in a targeted manner. However, in many cases, limited progress has been made in clinical adoption of such approaches. This in part results from a lack of safe and effective vaccine adjuvants that can be used to promote protective immunity and/or reduce deleterious immune responses. Although somewhat simplistic, it is possible to divide therapeutic vaccine approaches into those targeting conditions where antibody responses can mediate protection and those where the principal focus is the promotion of effector and memory cellular immunity or the reduction of damaging cellular immune responses as in the case of autoimmune diseases. Clearly, in all cases of antigen‐specific immunotherapy, the identification of protective antigens is a vital first step. There are many challenges to developing therapeutic vaccines beyond those associated with prophylactic diseases including the ongoing immune responses in patients, patient heterogeneity, and diversity in the type and stage of disease. If reproducible biomarkers can be defined, these could allow earlier diagnosis and intervention and likely increase therapeutic vaccine efficacy. Current immunomodulatory approaches related to adoptive cell transfers or passive antibody therapy are showing great promise, but these are outside the scope of this review which will focus on the potential for adjuvanted therapeutic active vaccination strategies.Keywords
Funding Information
- European Cooperation in Science and Technology (CA16231)
This publication has 203 references indexed in Scilit:
- Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensVaccine, 2012
- Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccineProceedings of the National Academy of Sciences, 2011
- A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T‐cell immunity in vivoEuropean Journal of Immunology, 2011
- Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapyJournal of Immune Based Therapies and Vaccines, 2011
- Factors Associated With Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine TrialThe Journal of Infectious Diseases, 2011
- A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 InfectionThe Journal of Infectious Diseases, 2011
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosisScience Translational Medicine, 2010
- Synthesis of sialyl Lewisa (sLea, CA19-9) and construction of an immunogenic sLea vaccineCancer Immunology, Immunotherapy, 2009
- Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motilityNature Immunology, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002